Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Cagrilintide

A Study Looking at How Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-related Side Effects in People Who Are Overweight or Obese

Novo Nordisk · Phase 1 · Recruiting · Enrollment 100

NCT07411560

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Arm 1:Glucose dependent Insulinotropic Polypeptide(GIP)+Cagrilintide then Placebo GIP+Cagrilintiden/rn/rn/rn/r
Arm 2: Placebo GIP + Cagrilintide then GIP + Cagrilintiden/rn/rn/rn/r
Arm 3: GIP + Cagrilintide then Placebo GIP + Cagrilintiden/rn/rn/rn/r
Arm 4: Placebo GIP + Cagrilintide then GIP + Cagrilintiden/rn/rn/rn/r

Not shown

  • Arm 1:Glucose dependent Insulinotropic Polypeptide(GIP)+Cagrilintide then Placebo GIP+Cagrilintide: endpoint not reported
  • Arm 2: Placebo GIP + Cagrilintide then GIP + Cagrilintide: endpoint not reported
  • Arm 3: GIP + Cagrilintide then Placebo GIP + Cagrilintide: endpoint not reported
  • Arm 4: Placebo GIP + Cagrilintide then GIP + Cagrilintide: endpoint not reported